Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2019; 18(03): 283-286
DOI: 10.4103/wjnm.WJNM_48_18
Original Article

The effect of retinoic acid in the ability of cold solid thyroid nodule to take up radioactive iodine: A preliminary study

Andreas Lim
Department of Nuclear Medicine and Molecular Imaging, Faculty of Medicine, Dr. Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia
,
Hendra Budiawan
Department of Nuclear Medicine and Molecular Imaging, Faculty of Medicine, Dr. Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia
,
Budi Darmawan
Department of Nuclear Medicine and Molecular Imaging, Faculty of Medicine, Dr. Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia
,
Basuki Hidayat
Department of Nuclear Medicine and Molecular Imaging, Faculty of Medicine, Dr. Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia
,
Hadyana Sukandar
1   Department of Public Health, Universitas Padjadjaran, Bandung, Indonesia
,
Achmad Hussein Sundawa Kartamihardja
Department of Nuclear Medicine and Molecular Imaging, Faculty of Medicine, Dr. Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

One of the treatment options for benign thyroid nodules is radioactive iodine (RAI). However, this treatment is more effective for hot/warm solid thyroid nodules. Cold thyroid solid nodules are characterized by the lack of iodine uptake compared to normal thyroid tissue. Oral retinoic acid (RA) is a synthetic derivative of Vitamin A. The effect of RA on the uptake of RAI is still controversial. The aim of this study was to evaluate the effect of RA in the ability of a cold solid thyroid nodule to take up RAI. Individuals with a cold solid thyroid nodule based on ultrasonography and thyroid scintigraphy were included. Participants with liver dysfunction, smokers, and pregnant patients were excluded from the study. Each participant underwent thyroid uptake scintigraphy twice (pre- and post-RA consumption) using 35–37 MBq NaI-131. Participants consumed RA at a dose of 1 mg/kg body weight (BW) followed with 1.5 mg/kg BW. This study was approved by Dr. Hasan Sadikin General Hospital Ethic Committee. A total of 12 cold thyroid solid nodules were evaluated. The mean percentage of the nodule uptake value pre- and post-intervention was 1.11% and 0.62%, respectively (P = 0.004), while normal thyroid tissue uptake values pre- and post-intervention were 27.57% and 13.40%, respectively (P = 0.002). The percentage alteration of nodules and normal thyroid tissue uptake value were 42.4% and 51.5% lower, respectively (P = 0.354). This study showed that RA reduces the ability of cold solid thyroid nodule, as well as normal thyroid tissue, to take up RAI.

Keywords

Cold solid thyroid nodule - radioactive iodine therapy - retinoic acid

Financial support and sponsorship

Nil.




Publication History

Received: 08 May 2018

Accepted: 27 July 2018

Article published online:
22 April 2022

© 2019. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: The Whickham survey. Clin Endocrinol (Oxf) 1977;7:481-93.
  • 2 Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 1968;69:537-40.
  • 3 Chapman EM. History of the discovery and early use of radioactive iodine. JAMA 1983;250:2042-4.
  • 4 Ajjan RA, Kamaruddin NA, Crisp M, Watson PF, Ludgate M, Weetman AP, et al. Regulation and tissue distribution of the human sodium iodide symporter gene. Clin Endocrinol (Oxf) 1998;49:517-23.
  • 5 Cavalieri RR, McDouglas IR.In vitro isotopic tests and imaging. In: Braverman LE, Utiger R, editors. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. Philadelphia: Lippincott-Raven; 1996. p. 902-9.
  • 6 Russo D, Bulotta S, Bruno R, Arturi F, Giannasio P, Derwahl M, et al. Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. Eur J Endocrinol 2001;145:591-7.
  • 7 Syrenicz A, Wolny M, Kram A, Sworczak K, Syrenicz M, Garanty-Bogacka B, et al. Analysis of the sodium iodide symporter expression in histological slides from a nodular goiter. Arch Med Res 2007;38:219-26.
  • 8 Damle N, Patnecha M, Kumar P, Maharjan S, Bal C. Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience. Indian J Nucl Med 2011;26:144-8.
  • 9 Van Herle AJ, Agatep ML, Padua DN 3rd, Totanes TL, Canlapan DV, Van Herle HM, et al. Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. J Clin Endocrinol Metab 1990;71:755-63.
  • 10 Schreck R, Schnieders F, Schmutzler C, Köhrle J. Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994;79:791-8.
  • 11 Schmutzler C, Winzer R, Meissner-Weigl J, Köhrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997;240:832-8.
  • 12 Handkiewicz-Junak D, Roskosz J, Hasse-Lazar K, Szpak-Ulczok S, Puch Z, Kukulska A, et al. 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-functional metastatic thyroid cancer: A single-center, 53-patient phase 2 study. Thyroid Res 2009;2:8.
  • 13 Becker D, Charkes ND, Dworkin H, Hurley J, McDougall IR, Price D, et al. Procedure guideline for thyroid uptake measurement: 1.0. Society of nuclear medicine. J Nucl Med 1996;37:1266-8.
  • 14 Mortensen JD, Woolner LB, Bennett WA. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 1955;15:1270-80.
  • 15 Bennedbaek FN, Perrild H, Hegedüs L. Diagnosis and treatment of the solitary thyroid nodule. Results of a European survey. Clin Endocrinol (Oxf) 1999;50:357-63.
  • 16 Bennedbaek FN, Hegedüs L. Management of the solitary thyroid nodule: Results of a North American survey. J Clin Endocrinol Metab 2000;85:2493-8.
  • 17 Bonnema SJ, Bennedbaek FN, Wiersinga WM, Hegedüs L. Management of the nontoxic multinodular goitre: A European questionnaire study. Clin Endocrinol (Oxf) 2000;53:5-12.
  • 18 Bonnema SJ, Bennedbaek FN, Ladenson PW, Hegedüs L. Management of the nontoxic multinodular goiter: A North American survey. J Clin Endocrinol Metab 2002;87:112-7.
  • 19 Ross DS. Nonpalpable thyroid nodules – managing an epidemic. J Clin Endocrinol Metab 2002;87:1938-40.
  • 20 Hegedüs L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: Current status and future perspectives. Endocr Rev 2003;24:102-32.
  • 21 Filetti S, Durante C, Torlontano M. Nonsurgical approaches to the management of thyroid nodules. Nat Clin Pract Endocrinol Metab 2006;2:384-94.
  • 22 Nygaard B, Hegedüs L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf) 1999;50:197-202.
  • 23 Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 1999;159:1364-8.
  • 24 Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol (Oxf) 2007;66:757-64.
  • 25 Giguère V. Retinoic acid receptors and cellular retinoid binding proteins: Complex interplay in retinoid signaling. Endocr Rev 1994;15:61-79.
  • 26 Ross SA, McCaffery PJ, Drager UC, De Luca LM. Retinoids in embryonal development. Physiol Rev 2000;80:1021-54.
  • 27 Lippman SM, Meyskens FL Jr. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 1987;107:499-502.
  • 28 Li G, Walch E, Yang X, Lippman SM, Clifford JL. Cloning and characterization of the human retinoid X receptor alpha gene: Conservation of structure with the mouse homolog. Biochem Biophys Res Commun 2000;269:54-7.
  • 29 Saade M, Debahy NE, Houjeily S. Clinical remission of xeroderma pigmentosum-associated squamous cell carcinoma with isotretinoin and chemotherapy: Case report. J Chemother 1999;11:313-7.
  • 30 Silva AC, Marassi MP, Mühlbauer M, Lourenço AL, Carvalho DP, Ferreira AC, et al. Retinoic acid effects on thyroid function of female rats. Life Sci 2009;84:673-7.
  • 31 Adamali HI, Gibney J, O'Shea D, Casey M, McKenna TJ. The occurrence of hypothyroidism following radioactive iodine treatment of toxic nodular goiter is related to the TSH level. Ir J Med Sci 2007;176:199-203.